Kallend, David

Effects of dalcetrapib in patients with a recent acute coronary syndrome

Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 2,022

Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol

Ray, K. K., Wright, R. S., Kallend, D., Koenig, W., Leiter, L. A., Raal, F. J., Bisch, J. A., Richardson, T., Jaros, M., Wijngaard, P. L. J., et al. (2020) · New England Journal of Medicine

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 1,665

Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol

Ray, K. K., Landmesser, U., Leiter, L. A., Kallend, D., Dufour, R., Karakas, M., Hall, T., Troquay, R. P. T., Turner, T., Visseren, F. L. J., et al. (2017) · New England Journal of Medicine

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 992

Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia

Raal, F. J., Kallend, D., Ray, K. K., Turner, T., Koenig, W., Wright, R. S., Wijngaard, P. L. J., Curcio, D., Jaros, M. J., Leiter, L. A., et al. (2020) · New England Journal of Medicine

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 818

A highly durable RNAi therapeutic inhibitor of PCSK9

Fitzgerald, K., White, S., Borodovsky, A., Bettencourt, B. R., Strahs, A., Clausen, V., Wijngaard, P., Horton, J. D., Taubel, J., Brooks, A., et al. (2017) · New England Journal of Medicine

Lipoproteins and Cardiovascular HealthRNA Interference and Gene Delivery

Cited by 768

Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins

Schwartz, G. G., Abt, M., Bao, W., DeMicco, D., Kallend, D., Miller, M., Mundl, H., & Olsson, A. G. (2015) · Journal of the American College of Cardiology

Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research

Cited by 272

Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis

Wright, R. S., Ray, K. K., Raal, F. J., Kallend, D. G., Jaros, M., Koenig, W., Leiter, L. A., Landmesser, U., Schwartz, G. G., Friedman, A., et al. (2021) · Journal of the American College of Cardiology

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 229

Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels: One-Year Follow-up of the ORION-1 Randomized Clinical Trial

Ray, K. K., Stoekenbroek, R. M., Kallend, D., Nishikido, T., Leiter, L. A., Landmesser, U., Wright, R. S., Wijngaard, P. L. J., & Kastelein, J. J. P. (2019) · JAMA Cardiology

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 172

Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1

Ray, K. K., Stoekenbroek, R. M., Kallend, D., Leiter, L. A., Landmesser, U., Wright, R. S., Wijngaard, P., & Kastelein, J. J. P. (2018) · Circulation

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 154

Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial

Leiter, L. A., Teoh, H., Kallend, D., Wright, R. S., Landmesser, U., Wijngaard, P. L. J., Kastelein, J. J. P., & Ray, K. K. (2019) · Diabetes Care

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 117

Effect of inclisiran on lipids in primary prevention: the ORION-11 trial

Ray, K. K., Kallend, D., Leiter, L. A., Raal, F. J., Koenig, W., Jaros, M. J., Schwartz, G. G., Landmesser, U., Garcia Conde, L., Wright, R. S., et al. (2022) · European Heart Journal

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 116

Inclisiran Durably Lowers Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin/Kexin Type 9 Expression in Homozygous Familial Hypercholesterolemia: The ORION-2 Pilot Study

Hovingh, G. K., Lepor, N. E., Kallend, D., Stoekenbroek, R. M., Wijngaard, P. L. J., & Raal, F. J. (2020) · Circulation

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 113

Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1

Landmesser, U., Haghikia, A., Leiter, L. A., Wright, R. S., Kallend, D., Wijngaard, P., Stoekenbroek, R., Kastelein, J. J., & Ray, K. K. (2021) · Cardiovascular Research

Lipoproteins and Cardiovascular HealthRNA Interference and Gene Delivery

Cited by 83

Pharmacokinetics and pharmacodynamics of inclisiran, a small interfering RNA therapy, in patients with hepatic impairment

Kallend, D., Stoekenbroek, R., He, Y., Smith, P. F., & Wijngaard, P. (2022) · Journal of Clinical Lipidology

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 73

Efficacy and safety of inclisiran in patients with established cerebrovascular disease: pooled, post hoc analysis of the ORION-9, ORION-10 and ORION-11, phase 3 randomised clinical trials

Koenig, W., Ray, K. K., Kallend, D. G., Landmesser, U., Leiter, L. A., Schwartz, G. G., Wright, R. S., Garcia Conde, L., Jaros, M., & Raal, F. J. (2021) · European Heart Journal

Lipoproteins and Cardiovascular HealthAcute Ischemic Stroke Management

Cited by 3